Adrian Casillas

Adverse drug reactions: types and treatment options.

Marc A. Riedl, Adrian Casillas · PubMed · 2003 · 275 citations

Life Sciences, Immunology, Pharmacology +11

Prospective Study of Particulate Air Pollution Exposures, Subclinical Atherosclerosis, and Clinical Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air)

Joel D. Kaufman, Sara D. Adar, R. W. Allen et al. · American Journal of Epidemiology · 2012 · 152 citations · Full text

Public Health, Environmental Sciences, Health Sciences +17

Okadaic acid activates p42 mitogen-activated protein kinase (MAP kinase; ERK-2) in B-lymphocytes but inhibits rather than augments cellular proliferation: contrast with phorbol 12-myristate 13-acetate

Adrian Casillas, Kleicy Cavalcante Amaral, S Chegini-Farahani et al. · Biochemical Journal · 1993 · 58 citations · Full text

Life Sciences, Biochemistry, Immunology +16

Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product☆☆☆★

E. Richard Stiehm, Adrian Casillas, Jerry Z. Finkelstein et al. · Journal of Allergy and Clinical Immunology · 1998 · 44 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +4

Contrasting effects of two tumour promoters, phorbol myristate acetate and okadaic acid, on T-cell responses and activation of p42 MAP-kinase/ERK-2.

Marta Amaral, Adrian Casillas, André E. Nel · PubMed · 1993 · 36 citations

Life Sciences, Immunology, Oncology +16